Endometrial Cancer
853
218
281
313
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
88 trials with published results (10%)
Research Maturity
313 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
66 terminated out of 853 trials
82.6%
-4.0% vs benchmark
6%
55 trials in Phase 3/4
28%
88 of 313 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 313 completed trials
Clinical Trials (853)
Distance-Based Exercise to Preserve Function and Prevent Disability
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Tirzepatide in Obesity-Driven Endometrial Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Prehabilitation in Gynaecological Cancer Patients
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
DESTINY-PANTUMOUR04
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study)
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer